

Ref: FOI/GS/ID 6336

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

09 October 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the incidence and treatment of Lung cancer.

You asked:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- a. Afatinib*
- b. Alectinib*
- c. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel*
- d. Atezolizumab monotherapy*
- e. Bevacizumab*
- f. Brigatinib*
- g. Ceritinib*
- h. Crizotinib*
- i. Dacomitinib*
- j. Docetaxel monotherapy*
- k. Durvalumab*
- l. Erlotinib*
- m. Gefitinib*
- n. Gemcitabine*
- o. Necitumumab*
- p. Nintedanib with Docetaxel*
- q. Nivolumab*
- r. Osimertinib*
- s. Paclitaxel*
- t. Pembrolizumab chemo in combination*
- u. Pembrolizumab monotherapy*
- v. Pemetrexed*
- w. Pemetrexed with Carboplatin*

- x. *Pemetrexed with Cisplatin*
- y. *Ramucirumab*
- z. *Vinorelbine and cisplatin/carboplatin*

Q2. *Could you please provide the total number of patients with any treatment in the last three months for:*

- a. *Total non-small cell lung cancer (NSCLC)*
- b. *Squamous non-small cell lung cancer (Sq NSCLC)*
- c. *Non-squamous non-small cell lung cancer (Non-Sq NSCLC)*

Trust response:

- 1.
 - a. 1
 - r. 3
 - u. 3
 - z. 2
- 2.
 - a. 48
 - b. 8
 - c. 40